These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 25823025)

  • 1. Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways.
    Meng X; Carlson NR; Dong J; Zhang Y
    Oncogene; 2015 Nov; 34(46):5709-17. PubMed ID: 25823025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disruption of the RP-MDM2-p53 pathway accelerates APC loss-induced colorectal tumorigenesis.
    Liu S; Tackmann NR; Yang J; Zhang Y
    Oncogene; 2017 Mar; 36(10):1374-1383. PubMed ID: 27617574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The in vivo role of the RP-Mdm2-p53 pathway in signaling oncogenic stress induced by pRb inactivation and Ras overexpression.
    Pan W; Issaq S; Zhang Y
    PLoS One; 2011; 6(6):e21625. PubMed ID: 21747916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RPL23 Links Oncogenic RAS Signaling to p53-Mediated Tumor Suppression.
    Meng X; Tackmann NR; Liu S; Yang J; Dong J; Wu C; Cox AD; Zhang Y
    Cancer Res; 2016 Sep; 76(17):5030-9. PubMed ID: 27402081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An ARF-independent c-MYC-activated tumor suppression pathway mediated by ribosomal protein-Mdm2 Interaction.
    Macias E; Jin A; Deisenroth C; Bhat K; Mao H; Lindström MS; Zhang Y
    Cancer Cell; 2010 Sep; 18(3):231-43. PubMed ID: 20832751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of the Arf tumor suppressor in Emicro-Myc transgenic mice: longitudinal study of Myc-induced lymphomagenesis.
    Bertwistle D; Sherr CJ
    Blood; 2007 Jan; 109(2):792-4. PubMed ID: 16968893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development.
    Eischen CM; Alt JR; Wang P
    Oncogene; 2004 Nov; 23(55):8931-40. PubMed ID: 15467748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection against High-Fat-Diet-Induced Obesity in MDM2
    Liu S; Kim TH; Franklin DA; Zhang Y
    Cell Rep; 2017 Jan; 18(4):1005-1018. PubMed ID: 28122227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.
    Eischen CM; Weber JD; Roussel MF; Sherr CJ; Cleveland JL
    Genes Dev; 1999 Oct; 13(20):2658-69. PubMed ID: 10541552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis.
    Eischen CM; Roussel MF; Korsmeyer SJ; Cleveland JL
    Mol Cell Biol; 2001 Nov; 21(22):7653-62. PubMed ID: 11604501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
    Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
    Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant transformation of Slp65-deficient pre-B cells involves disruption of the Arf-Mdm2-p53 tumor suppressor pathway.
    Ta VB; de Bruijn MJ; ter Brugge PJ; van Hamburg JP; Diepstraten HJ; van Loo PF; Kersseboom R; Hendriks RW
    Blood; 2010 Feb; 115(7):1385-93. PubMed ID: 20008789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cooperativity of p19ARF, Mdm2, and p53 in murine tumorigenesis.
    Moore L; Venkatachalam S; Vogel H; Watt JC; Wu CL; Steinman H; Jones SN; Donehower LA
    Oncogene; 2003 Oct; 22(49):7831-7. PubMed ID: 14586409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma.
    Møller MB; Ino Y; Gerdes AM; Skjødt K; Louis DN; Pedersen NT
    Leukemia; 1999 Mar; 13(3):453-9. PubMed ID: 10086736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The RP-Mdm2-p53 pathway and tumorigenesis.
    Miliani de Marval PL; Zhang Y
    Oncotarget; 2011 Mar; 2(3):234-8. PubMed ID: 21406728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased Mdm2 expression inhibits tumor development and extends survival independent of Arf and dependent on p53.
    Eischen CM; Boyd K
    PLoS One; 2012; 7(9):e46148. PubMed ID: 23029416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss.
    Baudino TA; Maclean KH; Brennan J; Parganas E; Yang C; Aslanian A; Lees JA; Sherr CJ; Roussel MF; Cleveland JL
    Mol Cell; 2003 Apr; 11(4):905-14. PubMed ID: 12718877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p19ARF directly and differentially controls the functions of c-Myc independently of p53.
    Qi Y; Gregory MA; Li Z; Brousal JP; West K; Hann SR
    Nature; 2004 Oct; 431(7009):712-7. PubMed ID: 15361884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic MYC Induces the Impaired Ribosome Biogenesis Checkpoint and Stabilizes p53 Independent of Increased Ribosome Content.
    Morcelle C; Menoyo S; Morón-Duran FD; Tauler A; Kozma SC; Thomas G; Gentilella A
    Cancer Res; 2019 Sep; 79(17):4348-4359. PubMed ID: 31292158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ribosomal protein-Mdm2-p53 pathway coordinates nutrient stress with lipid metabolism by regulating MCD and promoting fatty acid oxidation.
    Liu Y; He Y; Jin A; Tikunov AP; Zhou L; Tollini LA; Leslie P; Kim TH; Li LO; Coleman RA; Gu Z; Chen YQ; Macdonald JM; Graves LM; Zhang Y
    Proc Natl Acad Sci U S A; 2014 Jun; 111(23):E2414-22. PubMed ID: 24872453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.